Analyst Ratings for Akero Therapeutics
Portfolio Pulse from Benzinga Insights
Akero Therapeutics (NASDAQ:AKRO) has received 6 bullish and no bearish ratings from analysts in the last quarter. The company's average 12-month price target is $62.67, which has increased by 11.26% over the past month.
October 11, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akero Therapeutics has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment and can impact a company's stock price. In this case, Akero Therapeutics has received 6 bullish ratings and no bearish ones, indicating a positive outlook from analysts. This could increase investor confidence in the company and potentially drive up its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100